Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 26Magnetic Resonance Spectroscopy 14Nivolumab 13Docetaxel 13Specimen Handling 11Radiotherapy 9Paclitaxel 9Radiosurgery 8Early Intervention, Educational 8Cyclophosphamide 8Gemcitabine 7atezolizumab 6Taxes 6Surveys and Questionnaires 6Standard of Care 6Psychiatric Rehabilitation 6Ipilimumab 6Carboplatin 6sargramostim 5Pemetrexed 5Methods 5motexafin gadolinium 4fludarabine 4X-Rays 4Interviews as Topic 4Immunoglobulin G 4Fluorouracil 4Educational Status 4Cisplatin 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × cyclopropapyrroloindole × Genitourinary × Clear all
NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3 Recruiting
200 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡